August 6, 2018 Harpoon Therapeutics Treats First Patient With HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Read full article